Medaus Recalls Hydroxy B12 Vials Due to Sterility Concerns
Medaus, Inc. is recalling specific lots of Hydroxy B12 5mg/mL vials because the company cannot ensure the product is sterile.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric for drug recalls involving potential serious health consequences.
Plain-English summary
Medaus, Inc. is recalling 210 mL of Hydroxy B12 5mg/mL vials with preservative (benzalkonium 0.01%) due to a lack of assurance of sterility. The affected product is distributed in 5 mL vials.
The recall covers ten specific lots with expiration dates of July 11, 2016. These lots were distributed nationwide in the United States, as well as in Japan and New Zealand.
Consumers and healthcare providers should stop using the affected lots and contact Medaus, Inc. for further instructions or a refund.
The recalled product
- Product
- HYDROXY B12 5MG/ML W/PRES (BENZALKONIUM 0.01%), 5ML Vials, MEDAUS PHARMACY
- Manufacturer
- Medaus, Inc.
- Category
- Drug — Injectable
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (11)
- Lot #: 160202-12
- BUD: 07/11/16
- Lot #: 160204-10
- Lot #: 160210-70
- Lot #: 160215-11
- Lot #: 160222-17
- Lot #: 160223-64
- Lot #: 160224-67
- Lot #: 160307-28
- Lot #: 160308-1
- Lot #: 160309-3
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 88 recalled by Medaus, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 88 products in this recall →Related recalls
Same manufacturer · Medaus, Inc.
See all →- SevereMedaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Taurine Vials Due to Lack of Sterility Assurance
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Lipo-Injection Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls B-Complex Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereMedaus Recalls Pyridoxine HCL Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereKey Pharmacy Recalls Methyl-B12 Injections Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereMedaus Recalls Magnesium Chloride Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls NA Ascorbate Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereWellness Pharmacy Recalls Methyl B12 Vials Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
- SevereMedaus Recalls Sodium Ascorbate Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-25